Deutsch English Français

Contact

EP3947349

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3947349

EP3947349 - PYRROLE COMPOUNDS [Right-click to bookmark this link]
Status	Examination is in progress Status updated on 26.10.2023 Database last updated on 28.06.2024
Former	Request for examination was made Status updated on 07.01.2022
Former	The international publication has been made Status updated on 09.10.2020
Most recent event Tooltip	30.03.2024	New entry: Renewal fee paid
Applicant(s)	For all designated states Aligos Therapeutics, Inc. 1 Corporate Drive, 2nd Floor South San Francisco, CA 94080 / US
	For all designated states Emory University 1599 Clifton Rd. NE 4th Floor, 1599-001-1AZ Atlanta, GA 30322 / US
	[2022/06]
Inventor(s)	01 / VENDEVILLE, Sandrine c/o Aligos Therapeutics, Inc. 1 Corporate Drive 2nd Floor South San Francisco, California 94080 / US
	02 / SMITH, David Bernard c/o Aligos Therapeutics, Inc. 1 Corporate Drive 2nd Floor South San Francisco, California 94080 / US
	03 / BEIGELMAN, Leonid c/o Aligos Therapeutics, Inc. 1 Corporate Drive 2nd Floor South San Francisco, California 94080 / US
	04 / SEREBRYANY, Vladimir c/o Aligos Therapeutics, Inc. 1 Corporate Drive 2nd Floor South San Francisco, California 94080 / US
	05 / SCHINAZI, Raymond F. c/o Emory University 1599 Clifton Road NE, 4th Floor, Mailstop 1599/001/1AZ Atlanta, Georgia 30322 / US
	06 / AMBLARD, Franck c/o Emory University 1599 Clifton Road NE, 4th Floor, Mailstop 1599/001/1AZ Atlanta, Georgia 30322 / US
	07 / BASSIT, Leda c/o Emory University 1599 Clifton Road NE, 4th Floor, Mailstop 1599/001/1AZ Atlanta, Georgia 30322 / US
	[N/P]
Former [2022/06]	01 / VENDEVILLE, Sandrine South San Francisco, California 94080 / US
	02 / SMITH, David Bernard South San Francisco, California 94080 / US
	03 / BEIGELMAN, Leonid South San Francisco, California 94080 / US
	04 / SEREBRYANY, Vladimir South San Francisco, California 94080 / US
	05 / SCHINAZI, Raymond F. Atlanta, Georgia 30322 / US
	06 / AMBLARD, Franck Atlanta, Georgia 30322 / US
	07 / BASSIT, Leda Atlanta, Georgia 30322 / US
Representative(s)	Zacco Sweden AB P.O. Box 5581 Löjtnantsgatan 21 114 85 Stockholm / SE
	[N/P]
Former [2022/06]	Zacco Sweden AB P.O. Box 5581 114 85 Stockholm / SE
Application number, filing date	20784496.0	01.04.2020
	[2022/06]
	WO2020US26116
Priority number, date	US201962828919P	03.04.2019 Original published format: US 201962828919 P
	US201962932686P	08.11.2019 Original published format: US 201962932686 P
	[2022/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2020205934
	Date:	08.10.2020
	Language:	EN
	[2020/41]
	Type:	A1 Application with search report
	No.:	EP3947349
	Date:	09.02.2022
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 08.10.2020 takes the place of the publication of the European patent application.
	[2022/06]
Search report(s)	International search report - published on:	AU	08.10.2020
	(Supplementary) European search report - dispatched on:	EP	21.10.2022
Classification	IPC:	C07D207/34, C07D405/12, C07D417/12, C07D413/12, C07D401/12, C07D403/12, C07D405/14, C07D409/12, C07D487/04, A61K31/40, A61K31/4025, A61K31/407, A61K31/4155, A61K31/4178, A61K31/4192, A61K31/4245, A61K31/427, A61K31/4439, A61K31/506, A61P31/20, C07F9/141	[2022/47]
	CPC:	A61K31/4025 (EP,IL,KR,US); C07D207/34 (EP,AU,IL,KR,US); A61K31/40 (EP,IL,KR,US); A61K31/4192 (EP,IL,KR,US); A61P31/14 (KR); A61P31/20 (AU,KR); (+) C07D401/12 (EP,AU,IL,KR,US); C07D403/12 (EP,AU,IL,KR,US); C07D405/04 (KR); C07D405/12 (EP,AU,IL,KR,US); C07D405/14 (EP,AU,KR); C07D409/12 (EP,AU,IL,KR,US); C07D413/12 (EP,AU); C07D417/12 (EP,AU); C07D487/04 (EP,AU,IL,KR,US); C07F9/094 (EP) (-)
	Former IPC [2022/06]	C07D207/34, C07D405/12, C07D417/12, C07D413/12, C07D401/12, C07D403/12, C07D405/14, C07D409/12, C07D487/04, A61K31/40, A61K31/4025, A61K31/407, A61K31/4155, A61K31/4178, A61K31/4192, A61K31/4245, A61K31/427, A61K31/4439, A61K31/506, A61P31/20
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/06]
Extension states	BA	17.09.2021
	ME	17.09.2021
Validation states	KH	17.09.2021
	MA	17.09.2021
	MD	17.09.2021
	TN	17.09.2021
Title	German:	PYRROLVERBINDUNGEN	[2022/06]
	English:	PYRROLE COMPOUNDS	[2022/06]
	French:	COMPOSÉS DE PYRROLE	[2022/06]
Entry into regional phase	17.09.2021	National basic fee paid
	17.09.2021	Search fee paid
	17.09.2021	Designation fee(s) paid
	17.09.2021	Examination fee paid
Examination procedure	02.02.2021	Request for preliminary examination filed International Preliminary Examining Authority: AU
	17.09.2021	Examination requested [2022/06]
	28.04.2023	Amendment by applicant (claims and/or description)
	25.10.2023	Despatch of a communication from the examining division (Time limit: M04)
	16.02.2024	Reply to a communication from the examining division
Fees paid	Renewal fee
	27.04.2022	Renewal fee patent year 03
	27.04.2023	Renewal fee patent year 04
	28.03.2024	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[E]WO2020169784 (JANSSEN SCIENCES IRELAND UNLIMITED CO [IE]) [E] 1,3-6,8,16,17,19 * claims 1, 14, 15 ** compounds 3-8, 10-13, 17-18, 20-32, etc. *
	International search	[X]WO2015011281 (JANSSEN R & D IRELAND [IE]) [X] 1-72, 77-93 * Abstract; Pages 23-84, Compounds 5, 9, 18, 24-31, 38-39, 41-43, 46, 51, 54-55, 57-58, 61, 64, 82-91, 93, 97 and 101; Page 12, line 24-Page 13, line 11; Claims 9-11; Pages 6-10, Formulae (I) and (IA) *;
		[X]WO2017156255 (UNIV EMORY [US]) [X] 1-72, 77-93 * Abstract; Compounds 8, 7a, 7b, 25, 47-48, 58, 63-66, 75 and 82 on pages 79-127; Page 50, V. Isotopes; Pages 52-56, Hepatitis B Therapies Table; Pages 50-51, VI. Methods of Treatment; Claim 35; Pages 13-14 formula (VI) *;
		[X]WO2018039531 (GILEAD SCIENCES INC [US]) [X] 1-72, 77-93 * Abstract; Pages 89-92, paragraphs [0190]-[0197]; Claims 58-75; paragraph [0036]; Example compounds 2, 6-7, 12, 17, 20, 24-26, 29, 31-32, 37, 43, 45-46, 48, 50-51, 53, 55, 59-60, 64-65, 69-70, 74-77, 84, 86, 88-94, 98, 101-103, 107, 111, 126, 130-131, 134 and 150 on pages 103-215; Formula (I) in Claim 1 *;
		[X]WO2018121689 (SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO LTD [CN]) [X] 1-2, 5-6, 21, 26, 28, 35, 37, 41, 49, 51, 56, 65, 72* Intermediate compound 17c, page 27, line 21 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p